STAMFORD, Conn. – July 19, 2019 — We are pleased to announce that Christian Mazzi, MD, BSBA/BA, MBA will be joining us as President and Executive Medical Director, Adlon Therapeutics L.P. He will report to Purdue Pharma L.P. President and CEO, Craig Landau, MD.

In addition to general management of Adlon Therapeutics, a wholly-owned subsidiary of Purdue, Christian will have accountability for Medical Affairs, Pharmacovigilance & Drug Safety for Purdue and certain of its subsidiaries.

“I’m pleased to welcome Christian into our organization and believe his unique blend of business and medical experience will complement and strengthen our management team,” said Craig Landau, MD, president and CEO, Purdue Pharma. “I’m confident in Christian’s ability to support our diverse emerging pipeline and believe his broad therapeutic area expertise will help advance our interests in oncology, sleep and non-opioid pain treatments. Christian’s collaborative nature and excellence in science will help us serve patients by advancing existing and new internal and external research.”

Dr. Mazzi brings more than 15 years of pharmaceutical industry experience and accomplishments as his career has advanced through a series of senior roles of increasing accountability and complexity, both in the US and internationally. Dr. Mazzi was a Partner at Bain & Company in Boston, Zurich and London where he was the Healthcare sector head. During his career, he has led assignments in strategy, acquisition, technology & pipeline valuation, and organizational integration and has been directly involved in the development and facilitation of multiple collaborations and partnerships. Most recently, Dr. Mazzi held leadership positions with Mundipharma, an independently associated company of Purdue. Dr. Mazzi is also a physician with training in internal medicine. He has worked across a broad portfolio of therapeutic areas and medical technologies, including: oncology, diabetes, trauma pain, specialty antibiotics, molecular diagnostics, and mental health.

“The opportunity to lead Adlon’s exploration of future partnerships and to oversee efforts to better understand Attention-Deficit/Hyperactivity Disorder (ADHD) and support education around safe and responsible stimulant medication use is exciting,” says Christian. “Not only do we have the opportunity to help certain adults and adolescents with ADHD, we also have the opportunity to uncover new information and drive patient-first scientific development.”

Dr. Mazzi’s qualifications also include international education – he holds a Masters of Business Administration (MBA) from INSEAD, a Medical Degree from the University of Sydney, and graduated from Boston University’s dual degree program (BUCOP) with a Bachelor of Arts in Biology and a Bachelor of Science in Business Administration (BSBA/BA).

About Adlon Therapeutics L.P.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders. Our initial focus is on adults and adolescents who have been diagnosed with ADHD. Adlon is a subsidiary of Purdue Pharma L.P. For more information, please visit

# # #

Media Contact: media@